In contrast, the biologic approach injects a genetically
engineered protein designed to knock out a tumor's ability to produce new blood vessels, thereby cutting off its capacity to grow.
Not exact matches
In December, Tehrani signed a deal with GlaxoSmithKline that will allow the pharmaceutical giant to test at least four of its drug candidates on a Zymeworks -
designed platform, which combines a computer simulation with a way of
engineering protein molecules and allows products to be refined before they move to expensive clinical trials.
The two Princeton Ph.D. s had an idea for a way to
engineer a microbe that could build vast amounts of
protein designed for specific functions.
Dr Baker explained: «Our work has implications not only for understanding the basic science of
protein folding and stability, but also for guiding the
design and
engineering of new
proteins and drug molecules.»
«Once we had
designed the system, we had to first go into the lab and attach these DNA strands to various
proteins we wanted to be able to control,» said study author Rebecca P. Chen, a doctoral student in chemical and biomolecular
engineering (no relation to Wilfred Chen).
Her research centers on
engineering the network of
proteins that interact with DNA to control the expression of inherited traits (epigenetics) with the aim of rationally
designing new biological systems with predictable, reliable behavior, and replacing «magic bullet medicine» with «smart medicine.»
Bioprocess
engineer Rafael Garcia of ARS and biochemical
engineer Zhiyou Wen of the Virginia Polytechnic Institute and State University in Blacksburg are
designing a study to grow EPA - and DHA - producing microbes using low - cost by - products of other processes, such as glycerol from biodiesel production and rendered animal
protein from slaughterhouses.
«It's an impressive accomplishment,» says Frances Arnold, a chemical
engineer at the California Institute of Technology in Pasadena who has applied evolution to
protein design.
Green's laboratory, which specializes in
designing new drug - delivery systems, worked with Campochiaro and Aleksander Popel, Ph.D., professor of biomedical
engineering, whose laboratory discovered the new drug — a short piece of
protein that blocks the growth of unwanted blood vessels.
«
Design of self - assembling
protein nanomachines starts to click: A nanocage builds itself from
engineered components.»
The
engineered cells contain an antibody - like
protein known as a chimeric antigen receptor (CAR), which is
designed to bind to a
protein called CD19 found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia.
«This cell - targeted EPO approach demonstrates a new theoretical basis for the rational
design of
engineered protein fusion drugs.»
In 2007, Dr. Welch joined DNA2.0 as director of gene
design to develop the company's capabilities in the areas of
protein expression and
engineering.
In the new research, his team used «
protein engineering» to attach 12 copies of a small
protein to a cube - shaped molecular cage, which was
designed by a former graduate student of Yeates».
Computational
protein engineering: Bridging the gap between rational
design and laboratory evolution.
Our current research focuses on the discovery and functional characterization of novel
proteins, the rational
engineering of
proteins with improved functional properties, and de novo
design of molecular scaffolds for a variety of biotechnological and biomedical applications.
Repeat
proteins are ideal choices for development of such systems as they: (i) possess a relatively simple relationship between sequence, structure and function; (ii) are modular and non-globular in structure; (iii) act as diverse scaffolds for the mediation of a diverse range of
protein —
protein interactions; and (iv) have been extensively studied and successfully
engineered and
designed.
An
engineer designing a
protein that has 1000 amino acids may choose among some 101300 different amino acid sequences.
Protein engineers, exploiting their freedom of
design, can work with sequences artificially selected for superior predictability and stability of folding.
A key insight is his proposal that the
engineering problem of
designing proteins to fold in a predetermined way is much easier than the scientific problem of predicting how natural
proteins fold.
The Meiler laboratory develops technologies to
engineer protein, for example through assembly of large
protein scaffolds from fragments (Fortenberry, C.; et al.; «Exploring symmetry as an avenue to the computational
design of large protein domains»; JACS 2011; 133; 18026 & Eisenbeis, S.; et al.; «Potential of Fragment Recombination for Rational Design of Proteins»; JACS 2012; 134;
design of large
protein domains»; JACS 2011; 133; 18026 & Eisenbeis, S.; et al.; «Potential of Fragment Recombination for Rational
Design of Proteins»; JACS 2012; 134;
Design of
Proteins»; JACS 2012; 134; 4019).
Professional Duties & Responsibilities Biomedical and biotechnology
engineer with background in
design of biomaterials, biosensors, drug delivery devices, microfrabrication, and tissue
engineering Working knowledge of direct cell writing and rapid prototyping Experience fabricating nanocomposite hydrogel scaffolds Proficient in material analysis, mechanical, biochemical, and morphological testing of synthetic and biological materials Extensive experience in bio-imaging processes and procedures Specialized in mammalian, microbial, and viral cell culture Working knowledge of lab techniques and instruments including electrophoresis, chromatography, microscopy, spectroscopy, PCR, Flow cytometery,
protein assay, DNA isolation techniques, polymer synthesis and characterization, and synthetic fiber production Developed strong knowledge of FDA, GLP, GMP, GCP, and GDP regulatory requirements Created biocompatible photocurable hydrogels for cell immobilization Formulated cell friendly prepolymer formulation Performed surface modification of nano - particle fillers to enhance their biocompatibility Evaluated cell and biomaterial interaction, cell growth, and proliferation
Designed bench - top experiments and protocols to simulate in vivo situations
Designed hydrogel based microfluidic prototypes for cell entrapment and cell culture utilizing computer - aided robotic dispenser Determined various mechanical, morphological, and transport properties of photocured hydrogels using Instron, FTIR, EDX, X-ray diffraction, DSC, TGA, and DMA Assessed biocompatibility of hydrogels and physiology of entrapped cells Evaluated intracellular and extracellular reactions of entrapped cells on spatial and temporal scales using optical, confocal, fluorescence, atomic force, and scanning electron microscopies
Designed various biochemical assays Developed thermosensitive PET membranes for transdermal drug delivery application using Gamma radiation induced graft co-polymerization of N - isopropyl acylamide and Acrylic acid Characterized grafted co-polymer using various polymer characterization techniques Manipulated lower critical solution temperature of grafted thermosensitive co-polymer Loaded antibiotic on grafted co-polymer and determined drug release profile with temperature Determined biomechanical and biochemical properties of biological gels isolated from marine organisms Analyzed morphological and mechanical properties of metal coated yarns using SEM and Instron Performed analytical work on pharmaceutical formulations using gas and high performance liquid chromatography Performed market research and analysis for medical textile company Developed and implement comprehensive marketing and sales campaign